NZ752353A - Antifungal dry powders - Google Patents

Antifungal dry powders

Info

Publication number
NZ752353A
NZ752353A NZ752353A NZ75235317A NZ752353A NZ 752353 A NZ752353 A NZ 752353A NZ 752353 A NZ752353 A NZ 752353A NZ 75235317 A NZ75235317 A NZ 75235317A NZ 752353 A NZ752353 A NZ 752353A
Authority
NZ
New Zealand
Prior art keywords
dry powders
antifungal
antifungal dry
itraconazole
leucine
Prior art date
Application number
NZ752353A
Other languages
English (en)
Inventor
Jean C Sung
Jason M Perry
David Hava
Robert Saunders
Hillary Tracy
Andrew O’Connor
Original Assignee
Pulmatrix Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmatrix Operating Co Inc filed Critical Pulmatrix Operating Co Inc
Publication of NZ752353A publication Critical patent/NZ752353A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NZ752353A 2016-10-14 2017-10-13 Antifungal dry powders NZ752353A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662408376P 2016-10-14 2016-10-14
PCT/US2017/056497 WO2018071757A1 (en) 2016-10-14 2017-10-13 Antifungal dry powders

Publications (1)

Publication Number Publication Date
NZ752353A true NZ752353A (en) 2023-06-30

Family

ID=60186406

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ752353A NZ752353A (en) 2016-10-14 2017-10-13 Antifungal dry powders

Country Status (12)

Country Link
US (3) US11116722B2 (enExample)
EP (1) EP3525759A1 (enExample)
JP (1) JP7085538B2 (enExample)
KR (1) KR102408798B1 (enExample)
CN (1) CN109996536B (enExample)
AU (1) AU2017341815B2 (enExample)
CA (1) CA3039485A1 (enExample)
IL (1) IL265913B2 (enExample)
MX (1) MX388733B (enExample)
NZ (1) NZ752353A (enExample)
RU (1) RU2766086C2 (enExample)
WO (1) WO2018071757A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2640921C2 (ru) * 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
WO2019204597A1 (en) * 2018-04-18 2019-10-24 Pulmatrix Operating Company, Inc Methods of treating fungal infections
US20210145739A1 (en) * 2018-04-18 2021-05-20 Pulmatrix Operating Company, Inc. Antifungal formulations for pulmonary administration comprising itraconazole
WO2021092349A1 (en) * 2019-11-08 2021-05-14 Scynexis, Inc. Lipid-based formulations of scy-078 salts
CN111658610B (zh) * 2020-07-31 2022-05-24 上海方予健康医药科技有限公司 一种供雾化器用的三氮唑类抗真菌药物的混悬液
IT202000030443A1 (it) 2020-12-10 2022-06-10 Zambon Spa Polvere inalabile comprendente voriconazolo in forma cristallina
IT202000030437A1 (it) 2020-12-10 2022-06-10 Zambon Spa Metodo per la realizzazione di una polvere inalabile comprendente voriconazolo
WO2023086013A2 (en) * 2021-11-09 2023-05-19 Agency For Science, Technology And Research A salt-based antifungal powder platform formulation for aerosolization
EP4452235A1 (en) * 2021-12-20 2024-10-30 Pulmatrix Operating Company, Inc. Dry powder formulations of narrow spectrum kinase inhibitors
CN120322221A (zh) 2022-06-21 2025-07-15 好利安科技有限公司 用于吸入的包含糖和脂质复合颗粒的结晶药物组合物及其制备方法
JP2025527578A (ja) 2022-08-18 2025-08-22 パルマトリックス オペレーティング カンパニー,インコーポレイテッド 吸入用血管新生阻害剤を用いてがんを治療する方法
WO2024049982A2 (en) 2022-08-31 2024-03-07 Pulmatrix Operating Company, Inc. Methods of using itraconazole dry powders
WO2025064631A1 (en) * 2023-09-20 2025-03-27 The Board Of Trustees Of The University Of Illinois Use of a dry powder inhaler to treat or prevent pulmonary fungal infections

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4097620A (en) 1977-05-02 1978-06-27 Xerox Corporation Magnetic toner particle coating process
US4916134A (en) 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
EP1343372A2 (en) * 2000-12-21 2003-09-17 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
ITMI20010357U1 (it) 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
AU2003302274A1 (en) 2002-12-31 2004-07-29 Novartis Ag Aerosolizable pharmaceutical formulation for fungal infection therapy
KR101511196B1 (ko) 2003-05-28 2015-04-10 노바르티스 아게 아미노산 및/또는 인지질로 부분 또는 완전 코팅된 수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의 분무 건조법
US20050048127A1 (en) 2003-07-22 2005-03-03 Larry Brown Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
WO2006026502A1 (en) 2004-08-27 2006-03-09 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
WO2007092088A1 (en) 2005-12-28 2007-08-16 Nektar Therapeutics Compositions comprising amphotericin b
CN101495096A (zh) * 2006-05-30 2009-07-29 伊兰制药国际有限公司 纳米微粒泊沙康唑制剂
AU2007323007A1 (en) 2006-08-11 2008-05-29 Panacea Biotec Limited Particles for delivery of active ingredients, process of making and compositions thereof
EP2227085A4 (en) 2007-12-06 2013-10-09 Berg Pharma Llc INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
WO2009103035A2 (en) 2008-02-13 2009-08-20 Board Of Regents, The University Of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
EP2095816A1 (en) 2008-02-29 2009-09-02 Schlichthaar, Rainer, Dr. Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety
EP2172193A1 (en) 2008-10-02 2010-04-07 Capsulution Nanoscience AG Improved nanoparticulate compositions of poorly soluble compounds
CA2809666C (en) 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
EA032840B8 (ru) 2011-06-22 2020-06-18 Вайоми Терапеутикс Лимитед Пролекарства на основе конъюгатов противогрибковых агентов и их применение
EP2601973A1 (en) * 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
US20180369513A1 (en) 2012-02-21 2018-12-27 Respira Therapeutics, Inc. Powder dispersion devices and methods
US9801855B2 (en) 2012-03-07 2017-10-31 National Institute Of Pharmaceutical Education And Research (Niper) Nanocrystalline solid dispersion compositions and process of preparation thereof
WO2014106727A1 (en) 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
MX2015013845A (es) * 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
CN104398497B (zh) * 2014-10-29 2017-11-24 中山大学 伊曲康唑吸入粉雾剂及其制备方法
CA2972826C (en) * 2015-01-14 2023-09-12 Respira Therapeutics, Inc. Powder dispersion methods and devices

Also Published As

Publication number Publication date
US20200129428A1 (en) 2020-04-30
KR102408798B1 (ko) 2022-06-13
MX388733B (es) 2025-03-20
JP7085538B2 (ja) 2022-06-16
IL265913A (en) 2019-06-30
RU2019114112A (ru) 2020-11-16
BR112019007459A2 (pt) 2019-07-16
AU2017341815A1 (en) 2019-05-02
RU2766086C2 (ru) 2022-02-07
IL265913B2 (en) 2024-07-01
CN109996536B (zh) 2023-03-07
MX2019004322A (es) 2019-12-11
CN109996536A (zh) 2019-07-09
CA3039485A1 (en) 2018-04-19
RU2019114112A3 (enExample) 2021-02-12
WO2018071757A1 (en) 2018-04-19
US20250221928A1 (en) 2025-07-10
KR20190068591A (ko) 2019-06-18
EP3525759A1 (en) 2019-08-21
AU2017341815B2 (en) 2023-06-15
US20240285523A1 (en) 2024-08-29
US11116722B2 (en) 2021-09-14
JP2019534270A (ja) 2019-11-28
IL265913B1 (en) 2024-03-01

Similar Documents

Publication Publication Date Title
NZ752353A (en) Antifungal dry powders
EP3518692A4 (en) EVAPORABLE TOBACCO WAX COMPOSITIONS AND CONTAINERS THEREFOR
HK1245589A1 (zh) 气溶胶生成材料和包括其的装置
EP4438132A3 (en) Stable microcapsule compositions
MX2022008902A (es) Articulo abrasivo que incluye particulas abrasivas conformadas.
GB201508670D0 (en) Aerosol generating material and devices including the same
EP3286996A4 (en) EXTENDED TYPE BASE POWDER RIDGE RIDGE MACHINE AND POWDER RIDGE BASE MACHINE
MX2016013468A (es) Articulo abrasivo que incluye particulas abrasivas conformadas.
IL263355A (en) Nicotine particles and preparations
TW201637267A (en) Powder, electrode and battery comprising such a powder
IL266526A (en) Recombinant virus, preparations containing it and its uses
IL265770A (en) Conjugates are intended for sstr and particles and their formulations
EP3222268A4 (en) Powder dispersant, powder-dispersed composition containing same, and cosmetic
IL272055A (en) 8,1-naphthyridinone compounds and their uses
IL263842A (en) Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof
IL271852A (en) Solid powder supplements containing quercetin, a process for their preparation and their formulations
MX2016017142A (es) Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma.
WO2016036960A8 (en) Therapeutic nanoparticles and related compositions, methods and systems
WO2015139020A3 (en) Vaccine compositions and methods for restoring nkg2d pathway function against cancers
PT3731815T (pt) Composição de cetamina em pó seco para utilização no tratamento de depressão através de administração pulmonar
CL2018002542A1 (es) Na2-imp deshidratada como agente antiaglomerante
PL3519512T3 (pl) Termoutwardzalne kompozycje do powlekania proszkowego zawierające nadtlenek dilauroilu
WO2017090038A3 (en) Particulate photoinitiators and uses thereof
IL266898B (en) Solid powder preparations, a process for their preparation, their formulations and their use
ZA202005050B (en) Polypeptide, compositions and uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2025 BY THOMSON REUTERS

Effective date: 20240903

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 OCT 2026 BY THOMSON REUTERS

Effective date: 20250901